Technical Analysis for GDTC - CytoMed Therapeutics Limited
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New Downtrend | Bearish | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Inside Day | Range Contraction | -1.29% | |
Gapped Up | Strength | -1.29% | |
Down 3 Days in a Row | Weakness | -1.29% | |
Oversold Stochastic | Weakness | -1.29% | |
Stochastic Buy Signal | Bullish | -2.01% | |
Volume Surge | Other | -2.01% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | 1 day ago |
Down 3% | 1 day ago |
Down 2 % | 1 day ago |
Down 1% | 1 day ago |
Possible NR7 | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 11/29/2023
CytoMed Therapeutics Limited Description
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore. CytoMed Therapeutics Limited operates as a subsidiary of Glorious Finance Ltd
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immune System Immunotherapy Cancer Treatment Immunotherapies Virotherapy Chimeric Antigen Receptor T Cell Natural Killer Cell Lymphocytes T Cells Human Cancers Pre Clinical Biopharmaceutical
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 9.25 |
52 Week Low | 2.36 |
Average Volume | 5,732 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 3.67 |
20-Day Moving Average | 3.72 |
10-Day Moving Average | 3.57 |
Average True Range | 0.17 |
RSI (14) | 36.31 |
ADX | 25.63 |
+DI | 11.22 |
-DI | 30.98 |
Chandelier Exit (Long, 3 ATRs) | 3.76 |
Chandelier Exit (Short, 3 ATRs) | 3.85 |
Upper Bollinger Bands | 4.13 |
Lower Bollinger Band | 3.31 |
Percent B (%b) | 0.12 |
BandWidth | 21.94 |
MACD Line | -0.08 |
MACD Signal Line | -0.04 |
MACD Histogram | -0.0429 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.66 | ||||
Resistance 3 (R3) | 3.67 | 3.58 | 3.62 | ||
Resistance 2 (R2) | 3.58 | 3.52 | 3.58 | 3.61 | |
Resistance 1 (R1) | 3.50 | 3.48 | 3.45 | 3.49 | 3.59 |
Pivot Point | 3.41 | 3.41 | 3.39 | 3.41 | 3.41 |
Support 1 (S1) | 3.33 | 3.35 | 3.29 | 3.33 | 3.23 |
Support 2 (S2) | 3.24 | 3.31 | 3.24 | 3.21 | |
Support 3 (S3) | 3.16 | 3.24 | 3.20 | ||
Support 4 (S4) | 3.16 |